NY-ESO-1 expression in hepatocellular carcinoma: A potential new marker for early recurrence after surgery

Xu,Heng; Gu,Na; Liu,Zhao-Bo; Zheng,Min; Xiong,Fang; Wang,Si-Ying; Li,Ning; Lu,Jun

doi:10.3892/ol.2011.441

NY-ESO-1 expression in hepatocellular carcinoma: A potential new marker for early recurrence after surgery

Authors:
- Heng Xu
- Na Gu
- Zhao-Bo Liu
- Min Zheng
- Fang Xiong
- Si-Ying Wang
- Ning Li
- Jun Lu
View Affiliations

Affiliations: Tumor Biotherapy Ward of Beijing YouAn Hospital, Capital Medical University, Beijing 100069, P.R. China, Hangzhou High Throughput Drug Screening Center, SanDun, Hangzhou 310030, P.R. China, Department of Pathophysiology, Anhui Medical University, Hefei 230032, P.R. China
Published online on: October 13, 2011 https://doi.org/10.3892/ol.2011.441
Pages: 39-44

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

NY-ESO-1 belongs to the cancer testis antigens (CTA) family, and is identified in a variety of tumors. Certain studies have demonstrated that NY-ESO-1 predicts tumor recurrence and treatment response. No reports are currently available regarding the correlation between NY-ESO-1 and the recurrence of hepatocellular carcinoma (HCC) following surgery. The purpose of the present study was to evaluate the association between NY-ESO-1 and relapse of HCC and to explore the possible mechanisms for this correlation. A total of 120 HCC patients were analyzed for the expression of NY-ESO-1 by immunohistochemistry (IHC). A stable NY-ESO-1 over-expressed HepG2 cell line (ESO-HepG2) was established to determine the biological effects of NY-ESO-1 on cell proliferation, cell cycle and migration by using the xCELLigence DP system, flow cytometry and xCELLigence SP system. NY-ESO-1 was positive in 28 of 120 (23.3%) HCC tumor tissues. NY-ESO-1 was not detectable in adjacent normal liver tissues. A close correlation was found between NY-ESO-1 expression and the recurrence of HCC following surgery (P=0.007). Kaplan-Meier analysis showed a shorter recurrence-free survival (RFS) for patients positive for NY-ESO-1 (log-rank test, P=0.003). The Cox regression model demonstrated that NY-ESO-1 expression was a significant independent predictor for the recurrence of HCC following curative surgery (P=0.022). Compared with HepG2 cells, ESO-HepG2 cells have increased migration but not proliferation ability. In conclusion, NY-ESO-1 expression is associated with worse HCC outcome following surgery, and the mechanism for this finding may be that NY-ESO-1 increases tumor cell migration.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2	Venook AP: Treatment of hepatocellular carcinoma: too many options? J Clin Oncol. 12:1323–1334. 1994.PubMed/NCBI
3	Chen YT, Scanlan MJ, Sahin U, et al: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 94:1914–1918. 1997. View Article : Google Scholar : PubMed/NCBI
4	Chen YT, Gure AO, Tsang S, et al: Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA. 95:6919–6923. 1998. View Article : Google Scholar : PubMed/NCBI
5	Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ and Rosenberg SA: A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol. 161:3598–3606. 1998.PubMed/NCBI
6	Perez D, Hauswirth F, Jager D, et al: Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors. Int J Cancer. 128:2947–2952. 2011. View Article : Google Scholar
7	Svobodova S, Browning J, Macgregor D, et al: Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. Eur J Cancer. 47:460–469. 2010. View Article : Google Scholar
8	Chen CH, Chen GJ, Lee HS, et al: Expressions of cancer-testis antigens in human hepatocellular carcinomas. Cancer Lett. 164:189–195. 2001. View Article : Google Scholar : PubMed/NCBI
9	Luo G, Huang S, Xie X, et al: Expression of cancer-testis genes in human hepatocellular carcinomas. Cancer Immun. 2:112002.PubMed/NCBI
10	Korangy F, Ormandy LA, Bleck JS, et al: Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res. 10:4332–4341. 2004. View Article : Google Scholar : PubMed/NCBI
11	Peng JR, Chen HS, Mou DC, et al: Expression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters. Cancer Lett. 219:223–232. 2005. View Article : Google Scholar : PubMed/NCBI
12	Zhang WM, Xiao G, Xie D, Zhang M, Guo AL and Wen JM: Correlation of NY-ESO-1 gene and protein expression to metastasis and clinicopathologic features of hepatocellular carcinoma. Ai Zheng. 24:622–626. 2005.PubMed/NCBI
13	Zhang WM, Xiao G, Zhang M, Guo AL, Dong Y and Wen JM: Expression of NY-ESO-1 and LAGE-1 cancer-testis antigens in hepatocellular carcinoma. Zhonghua Bing Li Xue Za Zhi. 34:202–205. 2005.PubMed/NCBI
14	Nakamura S, Nouso K, Noguchi Y, et al: Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma. J Gastroenterol Hepatol. 21:1281–1285. 2006. View Article : Google Scholar : PubMed/NCBI
15	Lu Y, Wu LQ, Lu ZH, Wang XJ and Yang JY: Expression of SSX-1 and NY-ESO-1 mRNA in tumor tissues and its corresponding peripheral blood expression in patients with hepatocellular carcinoma. Chin Med J (Engl). 120:1042–1046. 2007.PubMed/NCBI
16	Wang XY, Chen HS, Luo S, Zhang HH, Fei R and Cai J: Comparisons for detecting NY-ESO-1 mRNA expression levels in hepatocellular carcinoma tissues. Oncol Rep. 21:713–719. 2009.PubMed/NCBI
17	Abassi YA, Jackson JA, Zhu J, O’Connell J, Wang X and Xu X: Label-free, real-time monitoring of IgE-mediated mast cell activation on microelectronic cell sensor arrays. J Immunol Methods. 292:195–205. 2004. View Article : Google Scholar : PubMed/NCBI
18	Perez D, Herrmann T, Jungbluth AA, et al: Cancer testis antigen expression in gastrointestinal stromal tumors: new markers for early recurrence. Int J Cancer. 123:1551–1555. 2008. View Article : Google Scholar : PubMed/NCBI
19	Konishi J, Toyooka S, Aoe M, et al: The relationship between NY-ESO-1 mRNA expression and clinicopathological features in non-small cell lung cancer. Oncol Rep. 11:1063–1067. 2004.PubMed/NCBI
20	Velazquez EF, Jungbluth AA, Yancovitz M, et al: Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors. Cancer Immun. 7:112007.PubMed/NCBI
21	Zhou JX, Li Y, Chen SX and Deng AM: Expression and prognostic significance of cancer-testis antigens (CTA) in intrahepatic cholagiocarcinoma. J Exp Clin Cancer Res. 30:22011. View Article : Google Scholar : PubMed/NCBI